Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
Clinical trial NCT03805932 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03805932
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-03
- Primary completion
- 2023-07-07
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.